FAMOTIDINE by Hikma is 2 -receptors. Approved for older for the treatment of: peptic ulcer disease. First approved in 2002.
Drug data last refreshed 14h ago
2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.
Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
Worked on FAMOTIDINE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.